Study on Different Treatment Sequences for Newly Diagnosed Standard-Risk Multiple Myeloma

Sponsor: Janssen Research & Development, LLC

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT06577025

Provider View

This clinical trial is exploring different sequences of treatments for patients with newly diagnosed standard-risk multiple myeloma. The study aims to evaluate how well these treatments work over time, particularly looking for signs of potential cure after five years.

Patient Parameters

Program Overview

The goal of this study is to see how effective different sequences of treatments are for patients with newly diagnosed standard-risk multiple myeloma. Researchers are looking for signs of potential cure, defined as no detectable cancer cells and clear PET/CT scans after five years. They will also measure how long patients live without the disease getting worse, known as progression-free survival (PFS).

Eligibility Criteria

Inclusion Criteria

  • Have a new diagnosis of multiple myeloma (MM) based on international criteria.
  • Have standard-risk MM, classified as stage I or II.
  • Be considered fit or intermediate-fit according to a specific health assessment.
  • Have measurable disease, which means certain levels of proteins in the blood or urine.
  • Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.

Exclusion Criteria

  • Have any ongoing blood disorders or cancers other than MM that require treatment.
  • Have nerve damage or pain rated as Grade 2 or higher.
  • Have a history of brain or spinal cord involvement by MM.
  • Have had a stroke or seizure in the past six months.
  • Have plasma cell leukemia or other specific blood disorders.
  • Have high-risk disease features, such as certain genetic markers or tumors outside the bone marrow.
  • Test positive for HIV.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.